Biomet Earns European, U.S. OK for New Porous Material

Warsaw, Ind.-based Biomet Orthopedics LLC has announced the first clinical use of its Osseoti porous technology, which also earned CE mark and U.S. Food and Drug Administration clearance in November and December last year respectively. The G7 Osseoti shell is used in conjunction with Biomet’s G7 acetabular system, a multi-bearing acetabular platform used for both primary and revision hip arthroplasty.

Through the use of a proprietary manufacturing process, Osseoti porous technology uses human CT (computed tomography) data in combination with 3-D printing technology to build a structure that directly mimics the architecture of human cancellous bone. This process generates a single porous architecture that allows creation of complex shapes, while maintaining the consistent porosity and strength necessary to facilitate bone and tissue ingrowth and implant stability. When applied to the G7 acetabular system, this provides surgeons the benefits of highly porous technology in combination with a sizing rationale designed for hip stability, according to the company.

The addition of Osseoti porous technology to the G7 acetabular system expands Biomet’s portfolio of total hip constructs that combine rich clinical heritage with modern technological advancements.

Biomet makes both surgical and non-surgical orthopedic products.